Moving into a chronic indication with numerous approved drugs is a challenge that gives pause to drugmakers, even when millions of patients can't tolerate or don't respond to existing therapies. When the indication additionally falls into the central nervous system (CNS) space, which has bedeviled dozens of drug development attempts in recent years, all but the boldest in the field tend to focus their efforts elsewhere.